Trial Profile
An open-label, prospective study assessing impact on endothelial function after canakinumab treatment in patients with chronic gout
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Aug 2016
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Gout
- Focus Pharmacodynamics; Pharmacokinetics
- 12 Aug 2016 New trial record